MC

518.6

+1.13%↑

SANES

10.308

+2.94%↑

BBVA

19.5

+1.8%↑

BNP

90.81

+1.65%↑

CABK

10.14

+1.35%↑

MC

518.6

+1.13%↑

SANES

10.308

+2.94%↑

BBVA

19.5

+1.8%↑

BNP

90.81

+1.65%↑

CABK

10.14

+1.35%↑

MC

518.6

+1.13%↑

SANES

10.308

+2.94%↑

BBVA

19.5

+1.8%↑

BNP

90.81

+1.65%↑

CABK

10.14

+1.35%↑

MC

518.6

+1.13%↑

SANES

10.308

+2.94%↑

BBVA

19.5

+1.8%↑

BNP

90.81

+1.65%↑

CABK

10.14

+1.35%↑

MC

518.6

+1.13%↑

SANES

10.308

+2.94%↑

BBVA

19.5

+1.8%↑

BNP

90.81

+1.65%↑

CABK

10.14

+1.35%↑

Search

Sartorius Stedim Biotech.

Uždarymo kaina

SektoriusFinansų sektorius

169.55 -2.67

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

169

Max

174.2

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-28M

64M

Pardavimai

67M

772M

P/E

Sektoriaus vid.

66.019

26.803

Pelnas, tenkantis vienai akcijai

0.94

Pelno marža

9.097

Darbuotojai

10,134

EBITDA

555M

772M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+34.82% upside

Dividendai

By Dow Jones

Kitas uždarbis

2026-04-23

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-877M

17B

Ankstesnė atidarymo kaina

172.22

Ankstesnė uždarymo kaina

169.55

Naujienos nuotaikos

By Acuity

63%

37%

378 / 444 reitingas Finance

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bullish Evidence

Sartorius Stedim Biotech. Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-02-15 23:21; UTC

Įsigijimai, susijungimai, perėmimai

Qube Agrees to Takeover by MAM-Led Consortium Valuing Its Equity at $6.51 Billion

2026-02-15 23:45; UTC

Rinkos pokalbiai

Nikkei May Rise as Fears About AI Disruption Recede -- Market Talk

2026-02-15 23:40; UTC

Rinkos pokalbiai

Gold Falls on Possible Position Adjustments -- Market Talk

2026-02-15 23:06; UTC

Uždarbis

Thai Beverage: Spirits, Beer Businesses Posted Satisfactory EBITDA Growth, Alongside Profit Margin Expansion>Y92.SG

2026-02-15 23:04; UTC

Uždarbis

Thai Beverage 1Q Beer Business EBITDA THB4.64B, Up 4.7% on Year>Y92.SG

2026-02-15 23:04; UTC

Uždarbis

Thai Beverage 1Q Spirits Business EBITDA THB8.50B, Up 6.9% on Year >Y92.SG

2026-02-15 23:01; UTC

Uždarbis

Thai Beverage 1Q EBITDA THB16.75B, Up 1.8% on Year >Y92.SG

2026-02-15 23:01; UTC

Uždarbis

Thai Beverage 1Q FY Sales Revenue THB86.70B, Down 6.0% on Year>Y92.SG

2026-02-15 22:53; UTC

Įsigijimai, susijungimai, perėmimai

Qube: MAM-Led Offer Implies A$11.7 Billion Enterprise Value

2026-02-15 22:53; UTC

Įsigijimai, susijungimai, perėmimai

Qube: UniSuper to Transfer 15.07% Stake to Equivalent Ownership of Consortium Holding Structure

2026-02-15 22:52; UTC

Įsigijimai, susijungimai, perėmimai

Qube Shareholders to Receive A$5.20/Share in Cash

2026-02-15 22:52; UTC

Įsigijimai, susijungimai, perėmimai

Qube Holdings Agrees to Takeover by Macquarie Asset Management-Led Consortium

2026-02-15 22:22; UTC

Įsigijimai, susijungimai, perėmimai

BlueScope CEO Tania Archibald Speaking on a Call With Media

2026-02-15 22:17; UTC

Įsigijimai, susijungimai, perėmimai

BlueScope CEO: Stresses Whyalla Project Would Have to Make Sense to Shareholders

2026-02-15 22:16; UTC

Įsigijimai, susijungimai, perėmimai

BlueScope CEO: Some Job Cuts Inevitable to Ensure Company is Competitive

2026-02-15 22:14; UTC

Įsigijimai, susijungimai, perėmimai

BlueScope CEO: Higher Returns Tied to End of Capital Investment Program

2026-02-15 22:14; UTC

Įsigijimai, susijungimai, perėmimai

BlueScope Steel CEO: Higher Returns After Rebuffed Takeover Bid a 'Natural Coincidence'

2026-02-15 20:48; UTC

Uždarbis

BlueScope: Will Now Target Net Debt of Up to A$1.5 Billion; Will Surpass as Needed

2026-02-15 20:47; UTC

Uždarbis

BlueScope: Expects Full Benefits of Further A$150M Cost Savings in FY 2027

2026-02-15 20:46; UTC

Uždarbis

BlueScope: Recorded Net Annualized Cost Improvements of A$190 Million in 1H

2026-02-15 20:45; UTC

Uždarbis

BlueScope Expects a One-Third Lower 2H Result From Asia Business Vs 1H

2026-02-15 20:44; UTC

Uždarbis

BlueScope Expects 15% Higher 2H Result From North America Business Vs 1H

2026-02-15 20:44; UTC

Uždarbis

BlueScope Expects Lower 2H Result From Australia Business Vs 1H

2026-02-15 20:43; UTC

Uždarbis

BlueScope Expects 2H Underlying Ebit of A$620 Million-A$700 Million

2026-02-15 20:42; UTC

Uždarbis

BlueScope Net Debt A$2.2 Million at Dec. 31

2026-02-15 20:42; UTC

Uždarbis

BlueScope 1H Underlying Ebit A$557.5 Million, Up 81% On-Year

2026-02-15 20:41; UTC

Uždarbis

BlueScope 1H Underlying Ebitda A$915.3 Million, Up 39% On-Year

2026-02-15 20:40; UTC

Uždarbis

BlueScope 1H Underlying Profit A$382.0 Million Vs A$176.4 Million Year Prior

2026-02-15 20:40; UTC

Uždarbis

BlueScope 1H Sales Revenue From Continuing Ops A$8.22 Billion, Up 4% On-Year

2026-02-15 20:39; UTC

Uždarbis

BlueScope Intends to Spend A$310 Million on Buyback, Or Other Returns if Share Repurchases Limited

Akcijų palyginimas

Kainos pokytis

Sartorius Stedim Biotech. Prognozė

Kainos tikslas

By TipRanks

34.82% į viršų

12 mėnesių prognozė

Vidutinis 235.86 EUR  34.82%

Aukščiausias 260 EUR

Žemiausias 210 EUR

Remiantis 7 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Sartorius Stedim Biotech. kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

7 ratings

3

Pirkti

4

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

202.7 / 211.7Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Bullish Evidence

Vidutinės trukmės periodas

Strong Bullish Evidence

Ilgalaikis periodas

Strong Bullish Evidence

Rinkos nuotaikos

By Acuity

378 / 444 reitingas Finansų sektorius

Naujienos nuotaikos

Meškų rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Sartorius Stedim Biotech.

Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; biolayer interferometry instruments; microbiology enumeration, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; biomolecule analysis tools; flow cytometry; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; and weighing products. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production; process automation platform and software; and develops and produces transfection, as well as other DNA/RNA delivery reagents and plasmid DNA. It serves manufacturers of medications, vaccines, foods, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. As of December 31, 2023, Sartorius Stedim Biotech S.A. operates as a subsidiary of Sartorius AG.
help-icon Live chat